Kayne Anderson Rudnick Investment Management LLC boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 17.1% during the first quarter, Holdings Channel reports. The fund owned 109,005 shares of the life sciences company’s stock after purchasing an additional 15,926 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC’s holdings in Illumina were worth $33,867,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of ILMN. Vanguard Group Inc lifted its position in shares of Illumina by 1.8% in the 3rd quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock worth $3,976,649,000 after purchasing an additional 188,516 shares during the period. Oregon Public Employees Retirement Fund lifted its position in shares of Illumina by 66,581.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after purchasing an additional 10,546,495 shares during the period. Jennison Associates LLC lifted its position in shares of Illumina by 3.7% in the 1st quarter. Jennison Associates LLC now owns 5,679,678 shares of the life sciences company’s stock worth $1,764,619,000 after purchasing an additional 200,114 shares during the period. Geode Capital Management LLC lifted its position in shares of Illumina by 10.1% in the 4th quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock worth $555,173,000 after purchasing an additional 170,046 shares during the period. Finally, Norges Bank acquired a new position in shares of Illumina in the 4th quarter worth approximately $514,627,000. 89.69% of the stock is currently owned by hedge funds and other institutional investors.
Illumina stock opened at $344.00 on Monday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.33 and a current ratio of 3.66. Illumina, Inc. has a 12-month low of $268.62 and a 12-month high of $372.61. The firm has a market cap of $50.57 billion, a P/E ratio of 58.60, a P/E/G ratio of 2.40 and a beta of 1.06.
Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 25th. The life sciences company reported $1.60 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.34 by $0.26. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The company had revenue of $846.00 million for the quarter, compared to the consensus estimate of $838.70 million. During the same quarter in the previous year, the company earned $1.45 EPS. Illumina’s quarterly revenue was up 8.2% compared to the same quarter last year. On average, equities research analysts expect that Illumina, Inc. will post 6.68 EPS for the current fiscal year.
In related news, Director Robert S. Epstein sold 1,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $314.45, for a total transaction of $314,450.00. Following the transaction, the director now owns 4,256 shares in the company, valued at approximately $1,338,299.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Omead Ostadan sold 1,260 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $335.03, for a total transaction of $422,137.80. Following the transaction, the senior vice president now owns 11,945 shares in the company, valued at approximately $4,001,933.35. The disclosure for this sale can be found here. Insiders have sold a total of 50,291 shares of company stock worth $15,747,633 in the last quarter. 0.38% of the stock is owned by corporate insiders.
ILMN has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $339.00 price target on the stock in a research report on Friday, February 22nd. OTR Global downgraded shares of Illumina to a “positive” rating in a research report on Tuesday, April 2nd. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Tuesday, April 16th. Canaccord Genuity restated a “buy” rating and issued a $350.00 price target (down previously from $360.00) on shares of Illumina in a research report on Friday, April 26th. Finally, Wolfe Research initiated coverage on shares of Illumina in a research report on Thursday, May 30th. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Illumina has a consensus rating of “Buy” and a consensus price target of $354.35.
TRADEMARK VIOLATION WARNING: “Kayne Anderson Rudnick Investment Management LLC Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2019/06/17/kayne-anderson-rudnick-investment-management-llc-boosts-holdings-in-illumina-inc-nasdaqilmn.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: Should you buy a closed-end mutual fund?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.